HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Upswing in sales on beauty.com in the last two quarters indicates that consumers are migrating back to prestige beauty, says Drugstore.com VP and CFO Tracy Wright. Speaking at the Janney Capital Markets Consumer Conference May 26, Wright noted that during the recession, many consumers of premium items online switched to mass market items sold through sites like drugstore.com, but that trend has reversed in recent quarters. In February, the Bellevue, Wash.-based firm reported that beauty.com's net revenues advanced 28 percent in the fourth quarter (1"The Rose Sheet" Feb. 15, 2010). Drugstore.com's total prestige product business amounts to about $30 million. The company recently announced the launch of two new microsites - AllergySuperstore.com and TheNaturalStore.com - which both sell beauty products targeted to the specific needs of the sites' shoppers. The firm announced the launch of another microsite, DeluxeSalonSupply.com, May 10 (2"The Rose Sheet" May 17, 2010)

You may also be interested in...

Beauty.com revenue up 28% in Q4

Drugstore.com's fourth-quarter sales increased 25% from the comparable quarter last year to $117.4 mil. on the strength of strong Beauty.com and OTC sales, Bellevue, Wash.-based firm says Feb. 9. Revenue from Beauty.com increased 28% in the 14-week quarter, compared with a 13-week quarter last year. The firm reported overall sales of $412.8 mil. and a $1.4 mil. loss for the year, attributed to its agreement to purchase Salu Inc.'s SkinStore.com. Drugstore.com's results "firmly established our company as a clear leader in health and beauty online," CEO Dawn Lepore says

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts